As per their product portfolio progress, their Prolia for bone health has implemented programs to address issues like identifying alternate sites of care, mobile nurse administered injections and prescription fills at specialty and retail pharmacies. The firm sees solid growth prospects in Evenity, given its unique bone building profile and usage in high risk, post fracture patients. In cardiovascular segment, the overall Repatha prescriptions rose on a quarter-over-quarter basis but seeing fall in new prescriptions in April due to COVID-19. CVS also removed Repatha from its national formulary as of July 1st, which hurt its total prescription growth in the third quarter. In inflammation portfolio, Otezla TRx growth was strong driven by new to brand prescriptions as well as fall in NBRx volume for the overall psoriasis market due to COVID-19. The firm's biosimilar products generated $357 million in sales during the second quarter of 2020.